Kerecis has developed the unique, patent-pending MariGen™ Omega3 fish-skin acellular dermal matrix transplantation technology, where complete acellular fish skin is used for tissue regeneration by transplantation. The MariGen Omega3 transplantation technology is used to reconstruct the skin in chronic wounds, for hernia repair, breast reconstruction and for dura restoration. Other tissue-transplant products are based on tissues of human and porcine origin. The fish-skin-based MariGen Omega3 technology offers improved economics and clinical performance, as well as reduced disease transfer risk and no cultural constraints on usage.

About 1.4 million hernia repair operations are performed globally annually. A hernia is a defect in the abdominal wall through which the internal organs may protrude with only the skin as a cover. Complications may arise post-operatively, including rejection of the mesh that is used to repair the defect. Kerecis provides a unique abdominal wall reconstruction material that is re-vascularized and provides strong repair hold, a promise for patients with challenging hernias.
Every year about 34.5 million chronic wounds are treated globally. Kerecis is committed to the prevention and treatment of chronic wounds - that often are the consequence of diabetes and circulation complications. Chronic wounds cause patients severe emotional and physical stress and create a significant financial burden on patients and the whole healthcare system. In the chronic wound the balance between production and degradation of molecules is lost and degradation plays too large a role. Kerecis helps wound regain balance and heal.